Affymetrix and MPI Collaborate to Develop Cancer Treatment Products

Affymetrix Inc. (Nasdaq:AFFX) and Medical Prognosis Institute A/S (MPI), a leading cancer diagnostic development company based in Denmark, today announced that they have signed a Powered by Affymetrix(TM) (PbA) agreement. With this agreement, MPI gains non-exclusive access to Affymetrix microarray technology to develop and commercialize drug sensitivity prediction and prognostic products for patients with cancer.

Read the full press release.

Oct 1. 2008

Announcements

MPI publishes Exercise Response Predictor

MPI, together with...
Read more

New CEO as of January 1, 2010.
MPI is proud to announce...
Read more

Blind clinical validation of drug response predictor

...
Read more